[Clinical trial of UFT in recurrent or advanced cancer].
UFT, antitumor agent containing uracil and futraful (FT-207), was given orally to 14 patients with recurrent or advanced carcinomas (6 gastric, 5 colorectal and 3 other carcinomas) and the clinical effects were evaluated. One PR (partial response) 1 NC (no change) and 9 PD(progressive disease) were obtained among 11 evaluable patients. Response rate was 9.1% (1/11), and overall response rate was 14.3% (2/14). According to Karnofsky's criteria, 2 responders (better than I-A) were obtained and response rate was 15.4% (2/13).
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols; D003110:Colonic Neoplasms / Q000188:drug therapy; D004338:Drug Combinations / Q000008:administration & dosage; D004341:Drug Evaluation; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D012004:Rectal Neoplasms / Q000188:drug therapy; D012811:Sigmoid Neoplasms / Q000188:drug therapy; D005641:Tegafur / Q000008:administration & dosage*; D014498:Uracil / Q000008:administration & dosage*
D000970:Antineoplastic Agents; D004338:Drug Combinations; D005641:Tegafur; D014498:Uracil; D005472:Fluorouracil